Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novaccess Global Inc (OP: XSNX )

0.0112 +0.0022 (+24.44%)
Streaming Delayed Price Updated: 3:54 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,101
Open 0.0112
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0090
Today's Range 0.0112 - 0.0112
52wk Range 0.0037 - 0.1190
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
Via ACCESSWIRE
NovAccess Global Advisory on Annual Meeting of Shareholders
Via ACCESSWIRE

Performance

YTD
-60.00%
-60.00%
1 Month
+12.00%
+12.00%
3 Month
+60.00%
+60.00%
6 Month
-54.47%
-54.47%
1 Year
-90.51%
-90.51%

More News

Read More
NovAccess Global Announces New License to Advance its Immunotherapy Platform
Via ACCESSWIRE
NovAccess Global Announces $10.7 Million Financing
Via ACCESSWIRE
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
Via ACCESSWIRE
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
Via ACCESSWIRE
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Via ACCESSWIRE
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
Via ACCESSWIRE
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
Via ACCESSWIRE
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
Via ACCESSWIRE
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
Via ACCESSWIRE
NovAccess Global to Present at World Orphan Drug Congress
Via ACCESSWIRE
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Via ACCESSWIRE
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
Via ACCESSWIRE
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
Via ACCESSWIRE
NovAccess Global Announces Virtual Annual Shareholders' Meeting
Via ACCESSWIRE
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
Via ACCESSWIRE
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
Via ACCESSWIRE
NovAccess Global Announces Fireside Chat with Board Member Perspectives
Via ACCESSWIRE
NovAccess Global Announces Fireside Chat Series for the Investment Community
Via ACCESSWIRE
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
Via ACCESSWIRE
NovAccess Global Announces Uplisting to OTCQB
Via ACCESSWIRE
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Via ACCESSWIRE
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
Via ACCESSWIRE
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
From NovAccess Global Inc.
Via AccessWire
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.